Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 4Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Pulmonary Blastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Pancreatic Neoplasms 1Pain, Intractable 1Neuroblastoma 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Melanoma, Cutaneous Malignant 1Melanoma 1Lymphoma 1Li-Fraumeni Syndrome 1Leukemia, Plasma Cell 1Leukemia 1Legius syndrome 1Hematologic Neoplasms 1Gliosarcoma 1

Interventions

ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NIH × Neoplasms, Glandular and Epithelial × Clear all
NCT07574541 2026-06-04

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Institutes of Health Clinical Center (CC)

Phase 2 Not yet recruiting
52 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡